Abstract

Aim Characteristics of children with bronchiolitis requiring PICU, causative organisms, PICU length of stay and outcome. Methods Case control study of all patients Results 80 children were admitted with the following demographics: Median age 2 months, IQR: 4.5 months. 59/80 (74%) admissions matched seasonal distribution (November–March). 37/80 (46%) patients had comorbidities (prematurity, cardiac, immunodeficiency). Level of respiratory support: non-invasive ventilation: 5% (4/80), conventional ventilation: 72.5% (58/80), high frequency oscillation ventilation (HFOV): 21% (17/80) and one ECMO case. Comorbidity was a risk factor for HFOV in 65% (11/17). Indication for intubation was: apnoea 27/76 (36%), respiratory acidosis 49/76 (64%). Nasopharyngeal aspirate (NPA) was positive in 64/80: 31 RSV A, 14 RSV B, 8 Parainfluenza, 3 Rhinovirus, 3 CMV, 2 Metapneumovirus, 2 Adenovirus, and 1 Influenza A. Total RSV positive NPA: 45/80 (56%). 6/31 RSV A positive patients had non-typeable Haemophilus Influenzae (NTHi) with sightly longer median ventilation days (5.5 vs 4 days). RSV infection accounted for majority of HFOV children 59% (10/17), and was responsible for 59.3% (16/27) intubation for apnoea, 59.2% (29/49) for respiratory acidosis. Comorbidities group had longer ventilation days and PICU length of stay compared with patients with no associated morbidities (6 days vs 4 days, p Conclusions Bronchiolitis remains a common cause for seasonal admission to PICU with significant length of stay, morbidity, and mortality for those with comorbidities. Concern about its associated cost is still a major challenge. Respiratory acidosis was twice as common cause for intubation. RSV was the most common encountered pathogen (56%) despite palivizumab introduction in 2010. We noticed unclear association of NTHi with RSV A infection. It is interesting to review preterm children who had palivizumab to see if they are underrepresented in PICU and consider its use in immunocompromised children as they have a high mortality.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.